The recently announced ouster of Rep. Dingell from the chair of the House Energy and Commerce Committee is a positive development for biotech companies seeking to capitalize on FoB’s. Dingell was one of the main impediments to the enactment of FoB legislation for reasons that have never been clear to me.
As an aside, Dingell has served in the House of Representatives for 54 years (!), longer than all but one person in the history of the USA.
Market Data 
Markets 
AI
